Comparative Pharmacology
Head-to-head clinical analysis: HEPARIN UFH versus LIPO HEPIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HEPARIN UFH versus LIPO HEPIN.
Heparin (UFH) vs LIPO-HEPIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Heparin binds to antithrombin III, inducing a conformational change that accelerates the inactivation of thrombin (factor IIa) and factor Xa, thereby inhibiting coagulation.
LIPO-HEPIN (unfractionated heparin) binds to antithrombin III, accelerating the inactivation of thrombin (factor IIa) and activated factor X (Xa), thereby inhibiting coagulation.
Intravenous: Initial bolus of 80 units/kg (or 5000 units) followed by continuous infusion of 18 units/kg/h (or 1300 units/h), adjusted to maintain aPTT 1.5-2.5 times control. Subcutaneous: 5000 units every 8-12 hours for prophylaxis.
Initial IV bolus 80 units/kg, then continuous IV infusion 18 units/kg/hr; or subcutaneous 5000 units every 8-12 hours. Dose adjusted based on aPTT.
None Documented
None Documented
0.5–2 hours (dose-dependent; at therapeutic doses, ~1–2 h; with higher doses, up to 2.5 h). Clinical context: shorter half-life in pulmonary embolism; prolonged in hepatic or renal impairment.
1-2 hours (therapeutic doses); dose-dependent: 30-60 min at low doses, up to 4-6 hours at high doses. Heparin is eliminated by a saturable zero-order process, leading to nonlinear pharmacokinetics. Clinical context: prolonged half-life in renal impairment or hepatic disease.
Primarily cleared via reticuloendothelial system and metabolism; renal excretion of unchanged drug is minimal (<5%).
Renal: 30-60% as unchanged drug; minor biliary/fecal (<10%). Clearance predominantly via hepatic metabolism (desulfation) and reticuloendothelial system uptake.
Category A/B
Category C
Anticoagulant
Anticoagulant